|
Name |
Longichalasin B
|
| Molecular Formula | C30H37NO4 | |
| IUPAC Name* |
[(1R,2R,7S,11R,12S,14S,15R,16S)-16-benzyl-12-hydroxy-5,7,14-trimethyl-13-methylidene-18-oxo-17-azatricyclo[9.7.0.01,15]octadeca-3,5,9-trien-2-yl] acetate
|
|
| SMILES |
C[C@H]1CC=C[C@H]2[C@@H](C(=C)[C@H]([C@@H]3[C@@]2([C@@H](C=CC(=C1)C)OC(=O)C)C(=O)N[C@H]3CC4=CC=CC=C4)C)O
|
|
| InChI |
InChI=1S/C30H37NO4/c1-18-10-9-13-24-28(33)21(4)20(3)27-25(17-23-11-7-6-8-12-23)31-29(34)30(24,27)26(35-22(5)32)15-14-19(2)16-18/h6-9,11-16,18,20,24-28,33H,4,10,17H2,1-3,5H3,(H,31,34)/t18-,20+,24-,25-,26+,27-,28+,30+/m0/s1
|
|
| InChIKey |
GGQJVEJLGIJFPD-NUPIXCJZSA-N
|
|
| Synonyms |
Longichalasin B
|
|
| CAS | NA | |
| PubChem CID | 156581992 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 475.6 | ALogp: | 4.2 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 75.6 | Aromatic Rings: | 4 |
| Heavy Atoms: | 35 | QED Weighted: | 0.475 |
| Caco-2 Permeability: | -4.911 | MDCK Permeability: | 0.00002790 |
| Pgp-inhibitor: | 0.828 | Pgp-substrate: | 0.769 |
| Human Intestinal Absorption (HIA): | 0.023 | 20% Bioavailability (F20%): | 0.038 |
| 30% Bioavailability (F30%): | 0.007 |
| Blood-Brain-Barrier Penetration (BBB): | 0.757 | Plasma Protein Binding (PPB): | 82.61% |
| Volume Distribution (VD): | 1.994 | Fu: | 18.08% |
| CYP1A2-inhibitor: | 0.09 | CYP1A2-substrate: | 0.08 |
| CYP2C19-inhibitor: | 0.645 | CYP2C19-substrate: | 0.505 |
| CYP2C9-inhibitor: | 0.767 | CYP2C9-substrate: | 0.058 |
| CYP2D6-inhibitor: | 0.03 | CYP2D6-substrate: | 0.195 |
| CYP3A4-inhibitor: | 0.908 | CYP3A4-substrate: | 0.361 |
| Clearance (CL): | 8.671 | Half-life (T1/2): | 0.391 |
| hERG Blockers: | 0.348 | Human Hepatotoxicity (H-HT): | 0.815 |
| Drug-inuced Liver Injury (DILI): | 0.137 | AMES Toxicity: | 0.227 |
| Rat Oral Acute Toxicity: | 0.88 | Maximum Recommended Daily Dose: | 0.988 |
| Skin Sensitization: | 0.721 | Carcinogencity: | 0.105 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
| Respiratory Toxicity: | 0.961 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC006059 | ![]() |
1.000 | D01TSI | ![]() |
0.250 | ||
| ENC003955 | ![]() |
0.806 | D06CWH | ![]() |
0.248 | ||
| ENC003300 | ![]() |
0.766 | D0OB1J | ![]() |
0.245 | ||
| ENC004026 | ![]() |
0.752 | D0IN7I | ![]() |
0.245 | ||
| ENC004468 | ![]() |
0.750 | D0TB8C | ![]() |
0.243 | ||
| ENC004745 | ![]() |
0.750 | D09NNH | ![]() |
0.243 | ||
| ENC005441 | ![]() |
0.644 | D0V3ZA | ![]() |
0.243 | ||
| ENC005506 | ![]() |
0.634 | D0G1VX | ![]() |
0.241 | ||
| ENC005175 | ![]() |
0.634 | D0R1BD | ![]() |
0.240 | ||
| ENC003763 | ![]() |
0.634 | D0A5LH | ![]() |
0.238 | ||